The University of Southampton
University of Southampton Institutional Repository

Ligandless receptors find a role

Ligandless receptors find a role
Ligandless receptors find a role
The discovery that patients with chronic lymphocytic leukemia (CLL) who showed somatic hypermutation of their immunoglobulin heavy chain variable region genes (IGHV) lived on average 3 times longer than those who did not1,2 revolutionized the study of CLL and has greatly influenced the design and understanding of clinical trials. Assaying for such mutations seems complicated, and the prospect is sufficiently intimidating to deter most routine laboratories from offering the test. Instead, there has been a search for a surrogate marker, especially one that can be assayed by a familiar technique such as flow cytometry.
Originally, the expression of CD38 looked promising,1 but that was shown to be discordant with IGHV mutations in up to 30% of cases—so much so that it could be regarded as an independent prognostic factor. Moreover, it could change during the course of the disease.3 Gene-expression profiling of the 2 subtypes of CLL suggested that the Syk family tyrosine kinase gene ZAP-70 was the best discriminator between them,4 but translating this finding into a flow cytometry test has proven troublesome, and none of the many possible assays has gained universal acceptance. One commonly used assay shows only 77% concordance with IGHV mutations.5
The immunoglobulin superfamily is a large group of cell-surface and soluble proteins that share structural features with immunoglobulin molecules, and includes receptors, coreceptors, and costimulatory molecules. The well-known receptors for the Fc portion of immunoglobulin are members of this family. Recently, a large family of Fc-receptor–like molecules (FCRLs) with preferential expression on B lymphocytes has been discovered.6 Genes coding for them localize to chromosome 1q21. There is no convincing evidence that they bind immunoglobulin, and so far, they lack ligands. In this issue of Blood, Li and colleagues have demonstrated that some of the FCRLs are expressed more densely on CLL cells from patients with mutated IGHV genes than on those from patients with unmutated IGHV genes. A flow cytometric assay using a monoclonal antibody against FCRL2 and measuring mean fluorescence intensity (MFI) discriminated between CLL cells with mutated and unmutated IGHV genes with a concordance of 94.4%. Among 107 patients with CLL, median time to first treatment was more than 4 times as long for patients whose cells expressed FCRL2 with an MFI ratio of 4.2 or greater. FCRL2 seems to be stably expressed over time.
Should measurement of FCRL2 expression replace IGHV mutations as a prognostic marker? We must first see confirmation of these results in a rather larger series of patients, but given that DNA sequencing is cheaply available from commercial sources and that matching the sequence to the database is performed by a computer program, one wonders why so few laboratories have established the assay for IGHV mutations. In any event, discordances between the various prognostic markers and the clinical picture promise to give us a clearer insight into why some cases of CLL progress and some do not
gene mutation status, cd38 expression, time, chronic lymphocytic-leukemia, disease
0006-4971
2-3
Hamblin, T.J.
85c9639a-7cf1-4477-9267-e6d772ba66ab
Hamblin, T.J.
85c9639a-7cf1-4477-9267-e6d772ba66ab

Hamblin, T.J. (2008) Ligandless receptors find a role. Blood, 112 (1), 2-3. (doi:10.1182/blood-2008-03-144113).

Record type: Article

Abstract

The discovery that patients with chronic lymphocytic leukemia (CLL) who showed somatic hypermutation of their immunoglobulin heavy chain variable region genes (IGHV) lived on average 3 times longer than those who did not1,2 revolutionized the study of CLL and has greatly influenced the design and understanding of clinical trials. Assaying for such mutations seems complicated, and the prospect is sufficiently intimidating to deter most routine laboratories from offering the test. Instead, there has been a search for a surrogate marker, especially one that can be assayed by a familiar technique such as flow cytometry.
Originally, the expression of CD38 looked promising,1 but that was shown to be discordant with IGHV mutations in up to 30% of cases—so much so that it could be regarded as an independent prognostic factor. Moreover, it could change during the course of the disease.3 Gene-expression profiling of the 2 subtypes of CLL suggested that the Syk family tyrosine kinase gene ZAP-70 was the best discriminator between them,4 but translating this finding into a flow cytometry test has proven troublesome, and none of the many possible assays has gained universal acceptance. One commonly used assay shows only 77% concordance with IGHV mutations.5
The immunoglobulin superfamily is a large group of cell-surface and soluble proteins that share structural features with immunoglobulin molecules, and includes receptors, coreceptors, and costimulatory molecules. The well-known receptors for the Fc portion of immunoglobulin are members of this family. Recently, a large family of Fc-receptor–like molecules (FCRLs) with preferential expression on B lymphocytes has been discovered.6 Genes coding for them localize to chromosome 1q21. There is no convincing evidence that they bind immunoglobulin, and so far, they lack ligands. In this issue of Blood, Li and colleagues have demonstrated that some of the FCRLs are expressed more densely on CLL cells from patients with mutated IGHV genes than on those from patients with unmutated IGHV genes. A flow cytometric assay using a monoclonal antibody against FCRL2 and measuring mean fluorescence intensity (MFI) discriminated between CLL cells with mutated and unmutated IGHV genes with a concordance of 94.4%. Among 107 patients with CLL, median time to first treatment was more than 4 times as long for patients whose cells expressed FCRL2 with an MFI ratio of 4.2 or greater. FCRL2 seems to be stably expressed over time.
Should measurement of FCRL2 expression replace IGHV mutations as a prognostic marker? We must first see confirmation of these results in a rather larger series of patients, but given that DNA sequencing is cheaply available from commercial sources and that matching the sequence to the database is performed by a computer program, one wonders why so few laboratories have established the assay for IGHV mutations. In any event, discordances between the various prognostic markers and the clinical picture promise to give us a clearer insight into why some cases of CLL progress and some do not

This record has no associated files available for download.

More information

Published date: 2008
Keywords: gene mutation status, cd38 expression, time, chronic lymphocytic-leukemia, disease

Identifiers

Local EPrints ID: 62774
URI: http://eprints.soton.ac.uk/id/eprint/62774
ISSN: 0006-4971
PURE UUID: 161ab1d1-d6d5-4264-866b-d5cc23000bd4

Catalogue record

Date deposited: 05 Sep 2008
Last modified: 15 Mar 2024 11:32

Export record

Altmetrics

Contributors

Author: T.J. Hamblin

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×